Le Lézard
Classified in: Health
Subject: POL

DNA Diagnostics Center® Ready to Provide Expedited Legally-Binding Immigration DNA Testing for Border Families


FAIRFIELD, Ohio, June 22, 2018 /PRNewswire/ -- DNA Diagnostics Center® (DDC® or the Company), the world's largest immigration DNA testing company, is ready to assist in reuniting families by providing expedited, legally-binding AABB (DEFINE AABB)-accredited immigration DNA tests, including sending trained professionals to all detention facilities, ensuring legal chain-of-custody protocols are followed.

DDC provides AABB-accredited legal DNA relationship testing, including maternity and paternity testing. DDC is ready to help at the border with expedited, legally-binding testing services.

The United States Citizenship and Immigration Services (USCIS) oversees the regulations pertaining to immigration DNA testing and only laboratories authorized by the AABB may be used. In the current situation, paternity-, maternity-, and siblingship DNA tests adhering to AABB standards are acceptable?ancestry DNA tests are not a legally binding solution. 

DDC processes over 1 million DNA samples each year in our accredited laboratory and has helped millions of families since 1995. The Company is highly-experienced and well versed with testing requirements in accordance with the United States Department of State Foreign Affairs Manual (FAM) for conducting genetic testing to verify and establish relationship for purposes of immigration.

In addition, the Company has a long history providing contract services to other governmental agencies, both state and county, for relationship chain-of-custody tests related to Title IV-D parentage cases for enforcing child support.  DDC currently has contractual partnerships with 22 state agencies, including Texas, plus the District of Columbia for family relationship testing services. 

Connie Hallquist, President and Chief Executive Officer of DNA Diagnostics Center®, states: "DDC is standing by and ready to assist our country with the current immigration challenge on our border and with parent/child reunification. As the world leader in immigration DNA testing, we have the accreditations, processes, systems, capacity, and experience to quickly provide U.S. government-sanctioned immigration DNA tests."

Once DNA samples are received at our Ohio-based laboratory from our professional collection team, results are ready in 1-2 days.  Since 1995, DDC employees have been dedicated to providing trusted answers for families and government institutions and are ready to assist our country now.

About DNA Diagnostics Center®:
DNA Diagnostics Center® (DDC®), founded over twenty years ago, is one of the world's largest private DNA testing companies with offices in Fairfield, Ohio (United States) and London, England (United Kingdom). DDC® offers DNA testing for paternity, immigration, forensics, genetic traits of animals, and ancestry.

DDC® is accredited by the American Association of Blood Banks (AABB), The Ministry of Justice, The College of American Pathologists (CAP), and The Clinical Laboratory Improvement Amendment (CLIA). DDC is also accredited by ACLASS to meet the international standards of ISO 17025 and the American Society of Crime Laboratory Directors / Laboratory Accreditation Board-International (ASCLD/LAB).  For more information visit www.dnacenter.com.

SOURCE DNA Diagnostics Center, Inc.


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: